Expression of the human concentrative nucleotide transporter 1 (hCNT1) gene correlates with clinical response in patients affected by Waldenström's Macroglobulinemia (WM) and small lymphocytic lymphoma (SLL) undergoing a combination treatment with 2-chloro-2′-deoxyadenosine (2-CdA) and Rituximab

Leukemia Research

Volumn 34, Issue 4, 2010, Pages 454-457

  Rabascio, C ^a   Laszlo, D ^a   Andreola, G ^a   Saronni, L ^a   Radice, D ^a   Rigacci, L ^b   Fabbri, A ^c   Frigeri, F ^d   Calabrese, L ^a   Billio, A ^e   Bertolini, F ^a   Martinelli, G ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e Central Hospital   (Italy)

Author keywords

2CdA; hCNT1; Real time PCR

Indexed keywords

5' NUCLEOTIDASE; CLADRIBINE; CONCENTRATIVE NUCLEOTIDE TRANSPORTER 1; DEOXYCYTIDINE; DEOXYGUANOSINE KINASE; MESSENGER RNA; NUCLEOTIDE TRANSPORTER; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE 2; RITUXIMAB; TUMOR MARKER; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BONE MARROW CELL; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GENE EXPRESSION; GENETIC CORRELATION; HEART ATRIUM FIBRILLATION; HUMAN; HUMAN CELL; LYMPHOCYTOMA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; WALDENSTROEM MACROGLOBULINEMIA;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLADRIBINE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; MODELS, BIOLOGICAL; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; WALDENSTROM MACROGLOBULINEMIA;

EID: 76749145483     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.07.002     Document Type: Article

References (18)

1. Pangalis G.A., Nathwani B.N., and Rappaport H. Malignant lymphoma, well differentiated lymphocytic: its relationship with chronic lymphocytic leukemia and macroglobulinemia of Waldenström. Cancer 39 (1977) 999-1010
2. Dimopoulos M.A., Panayiotidis P., Moulopoulos L.A., Sfikakis P., and Dalakas M. Waldenström's macroglobulinemia: clinical features, complications, and management. J Clin Oncol 18 (2000) 214-226
3. Johnson S.A., Birchall J., Luckie C., Oscier D.G., Owen R.G., and Haemato-Oncology Task Force of the British Committee for Standards in Haematology. Guidelines on the management of Waldenström macroglobulinaemia. Br J Haematol 132 (2006) 683-697
4. Treon S.P., Gertz M.A., Dimopoulos M., et al. Update on treatment recommendations from the Third International Workshop on Waldenström's macroglobulinemia. Blood 107 (2006) 3442-3446
5. Treon S.P., Emmanouilides C., Kimby E., et al., Waldenström's Macroglobulinemia Clinical Trials Group. Extended rituximab therapy in Waldenström's macroglobulinemia. Ann Oncol 16 (2005) 132-138
6. Weber D.M., Dimopoulos M.A., Delasalle K., Rankin K., Gavino M., and Alexanian R. 2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenström's macroglobulinemia. Semin Oncol 30 2 (2003) 243-247
7. Zhu C., Johansson M., Permert J., and Karlsson A. Enhanced cytotoxicity of nucleoside analogs by overexpression of mitochondrial deoxyguano sinekinase in cancer cell lines. J Biol Chem 273 (1998) 14707-14711
8. Lotfi K., Juliusson G., and Albertioni F. Pharmacological basis for cladribine resistance. Leuk Lymphoma 44 (2003) 1705-1712 [Review]
9. Wright A.M., Paterson A.R., Sowa B., Akabutu J.J., Grundy P.E., and Gati W.P. Cytotoxicity of 2-chlorodeoxyadenosine and arabinosylcytosine in leukaemic lymphoblasts from paediatric patients: significance of cellular nucleoside transporter content. Br J Haematol 116 (2002) 528-537
10. Kawasaki H., Carrera C.J., Piro L.D., Saven A., Kipps T.J., and Carson D.A. Relationship of deoxycytidine kinase and cytoplasmic 5′-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood 81 (1993) 597-601
11. Cardoen S., Van den Neste E., Smal C., Rosier J.F., Ferrant A., Van den Berghe G., and Bontemps F. Effects of 2-chloro-2′-deoxyadenosine on the cell cycle in the human leukemia EHEB cell line. Nucleosides Nucleotides Nucleic Acids 23 (2004) 1425-1429
12. Cheson B.D., Pfistner B., Juweid M.E., Gascoyne R.D., Specht L., Horning S.J., Coiffier B., Fisher R.I., Hagenbeek A., Zucca E., Rosen S.T., Stroobants S., Lister T.A., Hoppe R.T., Dreyling M., Tobinai K., Vose J.M., Connors J.M., Federico M., and Diehl V. The International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol 25 (2007) 579-586
13. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25 (2001) 402-408
14. Damaraju V.L., Damaraju S., Young J.D., et al. Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene 22 (2003) 7524-7536
15. Pennycooke M., Chaudary N., Shuralyova I., Zhang Y., and Coe I.R. Differential expression of human nucleoside transporters in normal and tumor tissue. Biochem Biophys Res Commun 280 3 (2001) 951-959
16. Valdes R., Casado F.J., and Pastor-Anglada M. Cell-cycle-dependent regulation of CNT1, a concentrative nucleoside transporter involved in the uptake of cell-cycle-dependent nucleoside-derived anticancer drugs. Biochem Biophys Res Commun 296 3 (2002) 575-579
17. Dragan Y., Valdes R., Gomez-Angelats M., Felipe A., Javier Casado F., Pitot H., and Pastor-Anglada M. Selective loss of nucleoside carrier expression in rat hepatocarcinomas. Hepatology 32 2 (2000) 239-246
18. Farré X., Guillén-Gómez E., Sánchez L., Hardisson D., Plaza Y., Lloberas J., Casado F.J., Palacios J., and Pastor-Anglada M. Expression of the nucleoside-derived drug transporters hCNT1, hENT1 and hENT2 in gynecologic tumors. Int J Cancer 112 6 (2004) 959-966